STOCK TITAN

Celcuity Inc - CELC STOCK NEWS

Welcome to our dedicated news page for Celcuity (Ticker: CELC), a resource for investors and traders seeking the latest updates and insights on Celcuity.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Celcuity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Celcuity's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
earnings
Celcuity Inc

Nasdaq:CELC

CELC Rankings

CELC Stock Data

458.32M
9.87M
20.37%
66.42%
8.06%
Medical Laboratories
Health Care and Social Assistance
Link
United States
Minneapolis

About CELC

celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.